fluconazole has been researched along with Leishmaniasis in 6 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Leishmaniasis: A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Current drug regimens for cutaneous leishmaniasis (CL) include toxic systemic therapies such as amphotericin B (AB) and pentavalent antimonials." | 3.91 | Susceptibility testing of Leishmania spp. against amphotericin B and fluconazole using the Sensititre™ YeastOne™ YO9 platform. ( Boggild, AK; Challa, P; Kariyawasam, R; Lau, R, 2019) |
| "Oral fluconazole has been shown to be more effective than placebo in one instance: for Leishmania major cutaneous disease from Saudi Arabia." | 2.43 | Clinical status of agents being developed for leishmaniasis. ( Berman, J, 2005) |
| "Fluconazole treatment for 6 weeks speeds up the already-rapid cure rate of cutaneous disease due to Leishmania major." | 2.42 | Current treatment approaches to leishmaniasis. ( Berman, J, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ortalli, M | 1 |
| Varani, S | 1 |
| Rosso, C | 1 |
| Quintavalla, A | 1 |
| Lombardo, M | 1 |
| Trombini, C | 1 |
| Braga, SS | 1 |
| Kariyawasam, R | 1 |
| Challa, P | 1 |
| Lau, R | 1 |
| Boggild, AK | 1 |
| Berman, J | 2 |
| Iyer, SR | 1 |
| Iyer, RR | 1 |
3 reviews available for fluconazole and Leishmaniasis
| Article | Year |
|---|---|
Multi-target drugs active against leishmaniasis: A paradigm of drug repurposing.
Topics: Amphotericin B; Antifungal Agents; Drug Repositioning; Drug Resistance, Fungal; Fluconazole; Humans; | 2019 |
Current treatment approaches to leishmaniasis.
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Clinical Trials as Topic; Fluconazo | 2003 |
Clinical status of agents being developed for leishmaniasis.
Topics: Aminoquinolines; Antiprotozoal Agents; Fluconazole; Humans; Imiquimod; Ketoconazole; Leishmaniasis; | 2005 |
3 other studies available for fluconazole and Leishmaniasis
| Article | Year |
|---|---|
Evaluation of synthetic substituted 1,2-dioxanes as novel agents against human leishmaniasis.
Topics: Animals; Chlorocebus aethiops; Dioxanes; Drug Design; Humans; Leishmania; Leishmaniasis; Parasitic S | 2019 |
Susceptibility testing of Leishmania spp. against amphotericin B and fluconazole using the Sensititre™ YeastOne™ YO9 platform.
Topics: Amphotericin B; Fluconazole; Humans; Leishmania; Leishmaniasis; Microbial Sensitivity Tests; Parasit | 2019 |
Anti leishmanial therapy--the changing scene.
Topics: Antifungal Agents; Fluconazole; Humans; Ketoconazole; Leishmaniasis | 1995 |